Development of a novel glycoprotein serum biomarker for epithelial ovarian cancer with more superior diagnostic capability than CA125

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462538
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Tokai University
• Principal Investigator: MIKAMI Mikio 東海大学, 医学部, 教授 (30190606)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 卵巣癌 / 腫瘍マーカー / 糖蛋白質

Outline of Final Research Achievements

No useful biomarker is currently available for early detection of epithelial ovarian cancer (EOC). More than 100,000 glycopeptides of serum glycoproteins obtained from all stage EOC patients and non-cancer control women (including endometriomas: EM) were explored for a mass spectrum approach. A2160, a fully-sialylated alpha-chain of complement 4-binding protein, (C4BP) was identified. A2160 was significantly elevated in all stages of Clear cell carcinoma (CCC) patients compared to with EMs. Diagnostic accuracy of A2160 to distinguish early stage CCC from EMs is significantly higher than that of CA-125. In addition, fully-sialylated glycans had a higher accuracy for diagnosing EOC as compared to partially-sialylated glycans of C4BP. Our study suggested that A2160 may be a useful biomarker to distinguish early-stage CCC from EM. This new biomarker can be potentially applied for the monitoring of EM patients, which could make the early diagnosis of CCC possible.

Free Research Field

婦人科腫瘍